Evidence map›Paper›PMID 27687028›Full record

ArticleLupus2017

Breast cancer in systemic lupus.

S Bernatsky, R Ramsey-Goldman, M Petri, M B Urowitz, D D Gladman, P R Fortin, E Ginzler, J Romero-Diaz, C Peschken, S Jacobsen and 19 more

Erratum issuedOpen access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?International journal of molecular sciences · 2020
    Review
  12. Observational
  13. Article
  14. Anti-nuclear antibodies in patients with breast cancer.Clinical and experimental immunology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 9 countries.

S Bernatsky1 Faculty of Medicine, McGill University, Montreal, Canada.
R Ramsey-Goldman3 Feinberg School of Medicine, Northwestern University, Chicago, USA.
M Petri4 Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, USA.
M B Urowitz5 Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Canada.
D D Gladman5 Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Canada.
P R Fortin6 Division of Rheumatology, Centre de recherche du CHU de Québec-Université Laval, Quebec City, Canada.
E Ginzler7 State University of New York-Downstate Medical Center, New York, USA.
J Romero-Diaz8 Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico.
C Peschken9 University of Manitoba, Winnipeg, Canada.
S Jacobsen10 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
J G Hanly11 Division of Rheumatology, Dalhousie University and Nova Scotia Health Authority, Halifax, Canada.
C Gordon12 Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham: Rheumatology department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust and NIHR/Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital Birmingham; University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
O Nived13 Department of Rheumatology, Institution of Clinical Sciences, Lund University Hospital, Lund, Sweden.
E H Yelin14 Department of Medicine, University of California, San Francisco, USA.
D Isenberg15 Centre for Rheumatology Research, University College London, London, UK.
A Rahman15 Centre for Rheumatology Research, University College London, London, UK.
S-C Bae16 The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea.
L Joseph1 Faculty of Medicine, McGill University, Montreal, Canada.
T Witte17 Department of Clinical Immunology, Hannover Medical School, Hannover, Germany.
G Ruiz-Irastorza18 Autoimmune Diseases Research Unit, Department Of Internal Medicine, Hospital Universitario Cruces, University Of The Basque Country, Bizkaia, Spain.
C Aranow19 Feinstein Institute for Medical Research, New York, USA.
D Kamen20 Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, USA.
G Sturfeldt13 Department of Rheumatology, Institution of Clinical Sciences, Lund University Hospital, Lund, Sweden.
W D Foulkes21 Departments of Oncology, Human Genetics and Medicine, McGill University, Montreal, Canada.
J E Hansen22 Department of Therapeutic Radiology, Yale School of Medicine, New Haven, USA.
Y St Pierre2 Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Canada.
P Chrétien Raymer2 Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Canada.
B Tessier-Cloutier23 Department of Anatomical Pathology, University of British Colombia, Vancouver, Canada.
A E Clarke24 Division of Rheumatology, University of Calgary, Calgary, Canada.
McGill University · CALund University · SEMcGill University Health Centre · CAToronto Western Hospital · CAUniversity College London · GBDalhousie University · CAFeinstein Institute for Medical Research · USHanyang University Seoul Hospital · KRHospital de Cruces · ESInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXJohns Hopkins University · USMedical University of South Carolina · USMedizinische Hochschule Hannover · DENorthwestern University · USQueen Elizabeth Hospital Birmingham · GBRigshospitalet · DKSUNY Downstate Health Sciences University · USUniversité Laval · CAUniversity of British Columbia · CAUniversity of Calgary · CA

Funding

Study of Lupus Vascular and Bone Longterm EndpointsP60AR048098 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI DUNLOP, DOROTHY D. · 2002 to 2011
$11.4M
Lupus CohortR01AR043727 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 1997 to 2015
$8.2M
Cancer Risk: Advancing knowledge in systemic rheumatic diseaseR03CA173822 · NCI · MCGILL UNIVERSITY HEALTH CTR RES INST · PI BERNATSKY, SASHA RUTH, CLARKE, ANN ELAINE · 2013 to 2014
$138k
NCI NIH HHS R03 CA173822NIAMS NIH HHS P60 AR048098NIAMS NIH HHS R01 AR043727Wellcome Trust
6 · The paper itself

Abstract

Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE duration. Results There were 86 SLE breast cancers and 4498 female SLE cancer-free controls. Patients were followed on average for 7.6 years. Versus controls, SLE breast cancer cases tended to be white and older. Breast cancer cases were similar to controls regarding anti-dsDNA positivity, disease activity, and most drug exposures over time. In univariate and multivariate models, the principal factor associated with breast cancers was older age at cohort entry. Conclusions There was little evidence that breast cancer risk in this SLE sample was strongly driven by any of the clinical factors that we studied. Further search for factors that determine the lower risk of breast cancer in SLE may be warranted.

Indexed as

AdultAge FactorsBreast NeoplasmsCohort StudiesFemaleHumansInternational CooperationLupus Erythematosus, SystemicMiddle AgedMultivariate AnalysisProportional Hazards ModelsRisk FactorsBreast cancersystemic lupus erythematosus

Identifiers

PMID27687028
PMCPMC5250552
OpenAlexW2525033845

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.